Form 4: Adaptive Biotechnologies Exec Trades Shares

Adaptive Biotechnologies Corp. reports a transaction by Chief Commercial Officer Susan Bobulsky involving common stock.

Summary

• Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies Corp., engaged in a transaction involving the company's common stock.
• The transaction occurred on July 1, 2026, and involved the disposal of 487 shares of common stock at a price of $22 per share.
• Following this transaction, Bobulsky beneficially owns 406,288 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While a stock disposal by an executive can be a negative signal, the execution via a pre-established Rule 10b5-1 plan mitigates immediate concern, indicating a planned divestment rather than a reaction to adverse information.

Negatives

• A disposal of company stock by a key executive could be perceived negatively by the market, although it was executed under a pre-arranged trading plan.

Risks

• The disposal of shares by a Chief Commercial Officer, even under a Rule 10b5-1 plan, might raise concerns about insider confidence in the short term.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving executive stock transactions, are closely watched by investors as they can provide insights into insider sentiment. The execution of this trade under a Rule 10b5-1 plan suggests a pre-determined strategy rather than a reaction to recent company events.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a key executive, even under a 10b5-1 plan, with caution, potentially leading to short-term market reactions.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Transaction, Susan Bobulsky, Chief Commercial Officer, Rule 10b5-1